Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…
McAlinden Research PartnersJune 14, 2022
The acquisition of biotechnology firms is one of the most common ways big pharma replenishes their pipeline of new drugs. However,…
McAlinden Research PartnersMay 12, 2022
The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…
McAlinden Research PartnersJanuary 4, 2022
Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…
McAlinden Research PartnersDecember 22, 2021
Research into CRISPR gene editing technology continues to expand the amount of potential applications, while shrinking the actual size of proteins…
McAlinden Research PartnersSeptember 8, 2021
AI is transforming industries across every sector of the economy. Biotech and pharma are now experiencing a boom in AI initiatives…
McAlinden Research PartnersJuly 27, 2021
Promising developments in new gene editing trials continue to drive investor interest in the growing biotech sector. Potential advancements include the…
McAlinden Research PartnersJuly 22, 2021
Encouraging results from recent clinical trials testing the efficacy of using psychedelics like arketamine, LSD, and psilocybin to treat mental…
McAlinden Research PartnersMay 24, 2021
President Trump's bout of COVID-19 launched countless headlines regarding the some of the leading experimental treatments he'd be receiving - therapeutics…
McAlinden Research PartnersOctober 13, 2020
